An analysis of a large nationwide dataset finds that regardless of their socioeconomic status, triple-negative breast cancer is nearly twice as likely to be diagnosed in black women than in white women.
A nearly 20-year observational study involving more than 44,700 black women nationwide found that regular vigorous exercise offers significant protection against development of an aggressive subtype of breast cancer.
A breast cancer risk model for African-American women underpredicted individual risk and risk of estrogen receptor (ER)-negative disease.
Black women have the highest death rate from breast cancer of all racial and ethnic groups, and are 40% more likely to die of the disease than are white women, according to a new report from the CDC.
Increased risk for breast cancer death among black women is greatest during early postdiagnosis yearsNovember 13, 2012
Non-Hispanic black women with breast cancer, specifically estrogen-positive tumors, are at a significantly increased risk for breast cancer death compared with non-Hispanic white women. The difference is greatest in the first 3 years after diagnosis.
Race/ethnicity varied the associations between an extreme body mass index or high waist-to-hip ratio and increased risk for mortality among patients with breast cancer.
For female patients with an abnormal breast or cervical cancer screening result, patient navigation services help to decrease the time to diagnosis and helps vulnerable populations get the care they need in a timely manner.
In this second installment on disparate populations, the author focuses on the challenges to providing oncologic care to the black community.
Concerted efforts to prevent or detect colorectal cancer at earlier stages in black patients could improve the worsening black-white disparities uncovered in a recent analysis.
Cancer incidence rates in men declined by 0.6% per year and remained stable in women and cancer mortality fell by 1.8% per year for men and by 1.6% per year for women between 2004 and 2008.
African-American women with HR-positive breast cancer face higher risk for disease recurrence and inferior survival compared with women of other races, according to research presented at the CTRC-AACR San Antonio Breast Cancer Symposium.
A collection of recent articles from the medical literature discuss surgically removing and evaluating an increasing number of lymph nodes in patients with colorectal cancer; Black women with breast cancer have a greater chance of dying from the disease than white women; chemotherapy plus radiotherapy with or without resection (preferably lobectomy) are options for patients with stage IIIA (N2) non-small cell lung cancer; respecting the patient's preferences for treatment is a key component of high quality end of life care; and frankincense oil could prove a useful gift in the treatment of bladder cancer
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Some Early Breast Cancer Patients Should Have Breast Conservation Instead of Mastectomy
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Targeting AR Mutations Promising in Metastatic Prostate Cancer
- GUCS 2017: Early Immunotherapy Discontinuation in mRCC
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Myalgia-arthralgia Syndrome Associated With Taxanes in Patients with Breast Cancer
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|